Search results
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Reuters via AOL· 9 hours agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
Pfizer's drug for advanced lung cancer shows promising long-term trial results
CNBC· 8 hours agoPfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term...
Pfizer drug extends life for patients with rare lung cancer usually seen in nonsmokers
NBC Universal via AOL· 9 hours agoPfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for...
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 5 hours agoA month has gone by since the last earnings report for Pfizer (PFE). Shares have added about 1.8% in...
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer...
Benzinga· 3 hours agoOn Friday, Pfizer Inc PFE released longer-term follow-up results from the Phase 3 CROWN trial...
Pfizer says its its lung cancer drug Lorbrena could be a $1 billion blockbuster
Quartz· 6 hours agoPharma giant Pfizer said that its lung cancer drug Lorbrena could reach blockbuster status by 2030...
FDA approves Moderna’s mRNA RSV vaccine
The Hill via Yahoo News· 6 hours agoThe Food and Drug Administration (FDA) has approved Moderna’s RSV mRNA vaccine for adults older than 60 years. The approval makes RSV the second disease...
How To Earn $500 A Month From Pfizer Stock
Benzinga via Yahoo Finance· 6 hours agoShares of Pfizer Inc. (NYSE:PFE) closed higher during Thursday's session, with the company's stock adding around 10% over the past month. Pfizer recently...
Pfizer drug extends life for people with rare form of lung cancer
AFP via Yahoo News· 6 hours agoA Pfizer lung cancer drug has been shown to greatly reduce tumor progression and improve survival...
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
Motley Fool via Yahoo Finance· 13 hours agoFool.com contributor Parkev Tatevosian reviews Pfizer (NYSE: PFE) stock for passive income...
